Pricing Log in Create free account
Saturday 7 November 2026 Export ANIX’s income statement to Excel — free account

ANIXA BIOSCIENCES INC

ANIX Healthcare Biotechnology

ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00.

EPS
−14.3%
Free cash flow
−17.1%

Quarter to July 2026, against a year earlier

3.16 0.13 +4.29%
Market cap
$105.3M
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
n/a
Altman Z
14.47
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.52
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — 1 — — — — 2 8 — 7 3 —
Sell — — — — — — — — — — — —
Insider Ownership 4.01%

Capital & Financial Ratios $m

Size
Market Cap 105.34
Revenue ttm 0.97
Net income ttm (10.47)
Free cash flow ttm (7.38)
Net debt Q (13.86)
Valuation
P/E 0.00
Forward P/E (6.00) (negative: loss-making)
Price / sales 111.13 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 8.18 (above 6: high)
Financial health
Current ratio Q 8.55 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (9.61)
Growth
Revenue growth Q 0.00%
Operating income growth Q −12.36% (below 0%: shrinking)
EPS, this year +7.84%
EPS, next year A −1.06% (below 0%: weak)
Revenue, next year A −100.00% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +0.99%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 101×, against a ten-year median of 77.5×; over the ten years it ranged from 1.6× in 2016 to 189× in 2022.
P/S against its own 10 years 73.72%
10-year low 10-year high
P/B against its own 10 years 63.95%
10-year low 10-year high
EV/Sales against its own 10 years 81.27%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 24 20 15 14
Receivables 0 0 — —
Inventory — — — —
Other — — — —
25 21 16 15
2023 2024 2025 Q'26
Payables 0 1 0 0
ST’ Debt — — — —
Other — — — —
2 3 2 2

Compound Annual Growth %

10y 5y 3y
Sales (3.48%) (6.89%) (42.64%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 10.69% 11.04% (20.91%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.08 Actual −0.08

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.10 −0.07 Beat by 0.03
Q1 FY26 −0.09 −0.08 Beat by 0.01
Q2 FY26 −0.10 −0.07 Beat by 0.03
Q3 FY26 −0.08 −0.08 Met by 0.00
Q4 FY26 −0.08 — Reports 11 January 2027

EPS $

Jan Apr Jul Oct Year
’26 (0.08) (0.07) (0.08) — —
’25 (0.10) (0.09) (0.07) (0.09) (0.34)
’24 (0.10) (0.10) (0.10) (0.09) (0.39)
’23 (0.08) (0.07) (0.08) (0.09) (0.32)
’22 (0.13) (0.12) (0.09) (0.12) (0.45)
’21 (0.09) (0.08) (0.14) (0.13) (0.45)
’20 (0.13) (0.12) (0.11) (0.09) (0.45)
Fiscal quarters ending in the months shown.

Revenue $m

Jan Apr Jul Oct Year
’26 — — — — —
’23 — 0 — — 0
’21 1 — — 0 1
’19 — 0 — — 0
’18 — 1 0 0 1
’17 — — 0 — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jan Apr Jul Oct Year
’26 (3) (2) (2) — —
’25 (3) (2) (2) (1) (7)
’24 (2) (1) (3) (1) (7)
’23 (2) (1) (1) (2) (6)
’22 (1) (2) (1) (2) (6)
’21 (1) (1) (1) (1) (5)
’20 (2) (2) (1) (1) (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jan Apr Jul Oct Year
’26 (3) (2) (2) — —
’25 (3) (2) (2) (1) (7)
’24 (2) (1) (3) (1) (7)
’23 (2) (1) (1) (2) (6)
’22 (1) (2) (1) (2) (6)
’21 (1) (1) (1) (1) (5)
’20 (2) (2) (1) (1) (6)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to October

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jul ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 0 1 0 — 1 — 0 — — 1 (5.0%) — — — —
Gross margin, % 100.00 100.00 100.00 100.00 0.00 100.00 0.00 100.00 — — 0.00 0.0 pt
EBT (5) (5) (14) (12) (10) (13) (14) (10) (13) (11) (10) +9.1%
EBT margin, % (1,672.13) (1,381.79) (1,280.28) (4,727.48) 0.00 (2,564.06) 0.00 (4,728.57) 0.00 0.00 0.00 +1,672.1 pt
Net income (5) (5) (14) (12) (10) (13) (14) (10) (13) (11) (10) +9.1%
Per share, $
Per share, $ Revenue 0.03 0.03 0.06 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 n/m
Earnings (0.57) (0.58) (0.79) (0.59) (0.45) (0.45) (0.45) (0.32) (0.39) (0.34) (0.32) (5.6%)
Cash flow (0.39) (0.31) (0.24) (0.24) (0.28) (0.17) (0.21) (0.20) (0.23) (0.22) (0.22) (6.0%)
Capex (0.02) 0.00 0.00 (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow (0.40) (0.31) (0.24) (0.25) (0.28) (0.17) (0.21) (0.20) (0.23) (0.22) (0.22) (6.5%)
Book value 0.11 0.65 0.29 0.24 0.37 1.22 0.93 0.75 0.59 0.43 0.39 +16.0%
Shares, m 9 12 18 20 22 29 30 31 32 32 33 +15.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — 0.00 — 0.00 — — 0.00 0.0
P/S 132.13 33.01 48.39 56.21 — 190.90 — 100.72 — — 111.13 93.6
P/B 57.00 3.16 13.77 15.91 — 4.18 — 4.19 — — 8.18 16.4
EV/Sales 130.19 28.94 47.51 54.68 — 148.95 — 80.05 — — 100.73 81.7
EV/FCF (15.50) (5.80) (16.25) (15.13) — (23.15) — (12.60) — — (13.34) (14.7)
Cash, $m
Cash, $m Operating cash flow (3) (4) (4) (5) (6) (5) (6) (6) (7) (7) (7) +8.7%
Capex 0 0 0 0 0 0 — — — — 0 n/m
Free cash flow (4) (4) (4) (5) (6) (5) (6) (6) (7) (7) (7) +8.2%
Balance, $m
Balance, $m Working capital 3 6 4 5 8 35 28 23 19 14 13 +18.9%
Net debt (3) (7) (5) (6) (9) (36) (30) (24) (20) (15) (14) +18.7%
Shareholders’ equity 1 8 5 5 8 35 28 23 19 14 13 +34.2%
Returns, %
Returns, % ROA (67.05) (97.20) (183.42) (182.81) (127.24) (56.68) (40.78) (35.08) (53.29) (58.01) (63.45) +9.0 pt
ROIC 0.00 (350.46) (7,004.46) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (166.85) (157.77) (213.58) (233.04) (153.22) (60.21) (43.18) (38.05) (59.41) (66.55) (72.57) +100.3 pt
People
People Employees 7 7 8 8 4 5 5 5 5 4 — (6.0%)
Revenue/emp, $m 0.04 0.05 0.14 0.03 0.00 0.10 0.00 0.04 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Oct 2023 · latest quarter Apr 2023 · fundamentals updated 25 Oct 2026

ANIXA BIOSCIENCES INC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HUMA Humacyte, Inc. $109.9M — (loss-making) — (loss-making) +34.88% (above 0%: growing) n/m +17.85% (above 0%: growing) (203.20%) (6,649.26%) Compare
NERV Minerva Neurosciences, Inc $109.8M — (loss-making) — (loss-making) — n/m −553.48% (below 0%: shrinking) 0.00% 0.00% Compare
OTLK Outlook Therapeutics, Inc. $106.9M — (loss-making) — (loss-making) −99.42% (below 0%: shrinking) n/m −76.54% (below 0%: shrinking) (95.40%) (124,255.17%) Compare
VYGR Voyager Therapeutics, Inc. $106.0M — (loss-making) — (loss-making) −69.97% (below 0%: shrinking) n/m +37.08% (above 0%: growing) 100.00% (658.25%) Compare
ANIX ANIXA BIOSCIENCES INC $105.3M — (loss-making) — (loss-making) 0.00% n/m −17.14% (below 0%: shrinking) 0.00% 0.00%
NBP NovaBridge Biosciences $105.3M — (loss-making) — (loss-making) −88.54% (below 0%: shrinking) n/m +34.25% (above 0%: growing) 100.00% 0.00% Compare
AVXL Anavex Life Sciences Corp. $102.9M — (loss-making) — — n/m +27.02% (above 0%: growing) — 0.00% Compare
HURA TuHURA Biosciences, Inc. $102.6M — (loss-making) — — n/m −70.46% (below 0%: shrinking) 0.00% 0.00% Compare
OKUR OnKure Therapeutics, Inc. $102.3M — (loss-making) — — n/m +22.05% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $105.7M — — −79.25% — +19.95% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 January 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.55m 3.71m 73.75
2024 3.48m 3.13m 62.50
2023 3.64m (2.62m) 56.43

Ownership

Directors and executive officers, together 26.40%
Dr. Amit Kumar 16.00%
Michael J. Catelani 6.90%
Lewis H. Titterton, Jr. 5.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

ANIXA BIOSCIENCES INC (ANIX) Latest News

26 Oct

Impact 4 · · PR Newswire

13 Oct

Impact 3 · · ACCESS Newswire
Impact 3 · · PR Newswire

5 Oct

Impact 4 · · PR Newswire

1 Oct

Impact 4 · · PR Newswire

21 Sep

Impact 4 ·

6 Jul

Impact 4 ·

29 Jun

Impact 3 ·

26 Jun

Impact 4 ·

1 Jun

Impact 3 · · PR Newswire

11 May

Impact 4 · · PR Newswire

29 Apr

Impact 4 ·

14 Apr

Impact 4 · · MarketBeat

1 Apr

Impact 4 · · PR Newswire

30 Mar

Impact 3 · · PR Newswire

13 Mar

Impact 3 · · MarketBeat

9 Mar

Impact 4 · · PR Newswire

10 Feb

Impact 4 · · MarketBeat

9 Feb

Impact 4 · · PR Newswire

8 Feb

Impact 3 · · Simply Wall St.

2 Feb

Impact 4 ·

27 Jan

Impact 4 · · PR Newswire

15 Dec

Impact 4 · · PR Newswire

11 Dec

Impact 4 · · PR Newswire

17 Nov

Impact 4 · · PR NewswireTipRanksMT NewswiresPharmaceutical TechnologyPharma VoiceMT NewswiresMT NewswiresMT Newswires

13 Nov

Impact 4 · · Simply Wall St.

12 Nov

Impact 4 · · PR NewswireInsider MonkeyPharma VoiceMT NewswiresInsider MonkeyFastCompanyMT NewswiresGuruFocus.com

5 Nov

Impact 4 · · Zacks
Impact 4 · · PR Newswire

20 Oct

Impact 4 · · PR Newswire
stockrow.com/ANIX · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com